

The Medical Letter[®]

on Drugs and Therapeutics

Volume 64

June 13, 2022

ISSUE No.
1652

IN THIS ISSUE

COVID-19 Update: NIH Recommends Against Ivermectinp 95

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 64 (Issue 1652)

June 13, 2022

COVID-19 UPDATE

NIH Recommends Against Ivermectin

On April 29, the NIH recommended against use of the antiparasitic drug ivermectin for treatment of COVID-19 outside of a clinical trial. The recommendation was made because recent randomized, placebo-controlled trials of ivermectin have produced negative results and because alternative drugs that have been shown to be effective for treatment of COVID-19 are available.¹

IVERMECTIN – Ivermectin has been used for years for treatment of infections caused by parasitic organisms such as *Strongyloides stercoralis* and *Onchocerca volvulus*. *In vitro*, high concentrations of ivermectin inhibit SARS-CoV-2 replication,² but achieving comparable concentrations of the drug in lung tissue or plasma would require doses much higher than those typically used in humans.³

CLINICAL STUDIES – In a randomized, double-blind trial, 1358 outpatient adults with COVID-19 and at least one risk factor for disease progression whose symptoms had begun ≤ 7 days previously received ivermectin 400 mcg/kg or placebo once daily for 3 days. The proportion of patients who required emergency department observation lasting > 6 hours or hospitalization due to COVID-19 within 28 days, the primary endpoint, did not differ significantly between the ivermectin and placebo groups (14.7% vs 16.3%; HR 0.90 [95% CI 0.70-1.16]).⁴

In another double-blind trial (IVERCOR-COVID19), 501 nonhospitalized adults in Argentina who had tested positive for SARS-CoV-2 infection ≤ 48 hours previously were randomized to receive ivermectin (12-24 mg based on weight) or placebo once daily for 2 days. The rate of hospitalization for any cause lasting ≥ 24 hours, the primary endpoint, did not differ significantly between the ivermectin and placebo groups (5.6% vs 8.4%; HR 0.65 [95% CI 0.32-1.31]). Time to hospitalization was also not significantly different between the two groups.⁵

In a third double-blind trial, 400 adults in Columbia with mild COVID-19 whose symptoms had begun ≤ 7 days previously were randomized to receive ivermectin 300 mcg/kg or placebo once daily for 5 days. The median time to symptom resolution, the primary endpoint, did not differ significantly between the ivermectin and placebo groups (10 vs 12 days; HR for resolution 1.07 [95% CI 0.87-1.32]).⁶

In an open-label trial in Malaysia (I-TECH), 490 adults ≥ 50 years old with mild to moderate COVID-19 whose symptoms had begun ≤ 7 days previously were randomized to receive ivermectin 400 mcg/kg or placebo once daily for 5 days. The rate of progression to severe disease (defined as a need for supplemental oxygen to maintain $SpO_2 \geq 95\%$), the primary endpoint, did not differ significantly between the ivermectin and placebo groups (21.6% vs 17.3%; RR 1.25 [95% CI 0.87-1.80]).⁷

RECOMMENDATIONS – The NIH recommends that nonhospitalized adults with COVID-19 be treated with either oral ritonavir-boosted nirmatrelvir (*Paxlovid*) or IV remdesivir (*Veklury*); ritonavir-boosted nirmatrelvir is preferred.⁸ Both of these therapies decreased the risk of hospitalization or death significantly more than placebo in large, randomized, double-blind trials.^{9,10} If these drugs are inappropriate or unavailable, use of molnupiravir (*Lagevrio*) or bebtelovimab (both available under FDA Emergency Use Authorization) is recommended.⁸ ■

1. NIH. COVID-19 treatment guidelines. Ivermectin. April 29, 2022. Available at: <https://bit.ly/3L7Jbhg>. Accessed May 23, 2022.
2. L Caly et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 *in vitro*. *Antiviral Res* 2020; 178:104787.
3. B Jermain et al. Development of a minimal physiologically-based pharmacokinetic model to simulate lung exposure in humans following oral administration of ivermectin for COVID-19 drug repurposing. *J Pharm Sci* 2020; 109:3574.
4. G Reis et al. Effect of early treatment with ivermectin among patients with COVID-19. *N Engl J Med* 2022; 386:1721.
5. J Vallejos et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. *BMC Infect Dis* 2021; 21:635.

6. E Lopez-Medina et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. *JAMA* 2021; 325:1426.
7. SCL Lim et al. Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: the I-TECH randomized clinical trial. *JAMA Intern Med* 2022; 182:426.
8. NIH. COVID-19 treatment guidelines. Therapeutic management of nonhospitalized adults with COVID-19. April 8, 2022. Available at: <https://bit.ly/3w5TdLB>. Accessed May 23, 2022.
9. J Hammond et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. *N Engl J Med* 2022; 386:1397.
10. RL Gottlieb et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. *N Engl J Med* 2022; 386:305.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:    

Copyright 2022. ISSN 0025-2859

